Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia (A-T). Dirk Thye, M.D., Quince's Chief Executive Officer and Chief ...

Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia (A-T). Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief ...

Phase 3 NEAT clinical trial nearing 50% enrollment; company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 Dirk Thye, M.D ...

Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia (A-T). Quince also disclosed that the company has enrolled 46 ...

Pivotal Phase 3 NEAT Clinical Trial Quince will host an investor webinar today focused on addressing the high unmet need in the company’s lead rare pediatric neurodegenerative disease indication, ...

1Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. *Corresponding Author: Jann N. Sarkaria, Department of Radiation Oncology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905.

“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...

Credit: Yelena Dokic, MD. A 60-year-old Black man with hypertension and type 2 diabetes presents with a 1-month history of a yellowish, green furry plaque on his tongue. A 60-year-old Black man with ...